SYMPAZAN Drug Patent Profile
✉ Email this page to a colleague
When do Sympazan patents expire, and when can generic versions of Sympazan launch?
Sympazan is a drug marketed by Otter Pharms and is included in one NDA. There is one patent protecting this drug.
This drug has six patent family members in six countries.
The generic ingredient in SYMPAZAN is clobazam. There are ten drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the clobazam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sympazan
A generic version of SYMPAZAN was approved as clobazam by AMNEAL on October 22nd, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SYMPAZAN?
- What are the global sales for SYMPAZAN?
- What is Average Wholesale Price for SYMPAZAN?
Summary for SYMPAZAN
International Patents: | 6 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 37 |
Patent Applications: | 4,144 |
Drug Prices: | Drug price information for SYMPAZAN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SYMPAZAN |
What excipients (inactive ingredients) are in SYMPAZAN? | SYMPAZAN excipients list |
DailyMed Link: | SYMPAZAN at DailyMed |


Pharmacology for SYMPAZAN
Drug Class | Benzodiazepine |
Mechanism of Action | Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inducers |
US Patents and Regulatory Information for SYMPAZAN
SYMPAZAN is protected by one US patents.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | RX | Yes | No | 11,541,002 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | RX | Yes | No | 11,541,002 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | RX | Yes | Yes | 11,541,002 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SYMPAZAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | 8,603,514 | ⤷ Try for Free |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | 8,765,167 | ⤷ Try for Free |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | 8,765,167 | ⤷ Try for Free |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | 8,765,167 | ⤷ Try for Free |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-003 | Nov 1, 2018 | 8,603,514 | ⤷ Try for Free |
Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | 8,603,514 | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SYMPAZAN
See the table below for patents covering SYMPAZAN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 3846778 | ⤷ Try for Free | |
World Intellectual Property Organization (WIPO) | 03030881 | ⤷ Try for Free | |
World Intellectual Property Organization (WIPO) | 2004066986 | ⤷ Try for Free | |
China | 102481250 | Sublingual And Buccal Film Compositions | ⤷ Try for Free |
Australia | 2011253023 | Film compositions for delivery of actives | ⤷ Try for Free |
Denmark | 2332523 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Market Dynamics and Financial Trajectory for Sympazan
More… ↓